The key steps to gaining drug approval in China include preclinical research, Investigational New Drug (IND) application, clinical trials (phases I-III), New Drug Application (NDA) submission, regulatory review by the National Medical Products Administration (NMPA), and post-approval monitoring. Compliance with Good Manufacturing Practices (GMP) is also essential.
